This phase II trial is evaluating an anti-epileptic drug as a way of controlling seizures in patients being treated for grade II-III gliomas.
This trial is treating patients with grade II-III gliomas.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Perampanel for the control of glioma associated seizures – efficacy and safety: a pilot phase II randomised controlled trial
Other Non-Commercial Sponsor
Royal Melbourne Hospital
This is a randomised clinical trial, in which patients, will be post-operatively randomised to receive either perampanel or levetiracetam for 52 weeks.
Not Recruiting Hospitals Read More